SEC Form 4 · accession 0001127602-16-041955

BIOGEN INC. · BIIB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Alfred Sandrock

Officer — EVP CMO Neuro & Neurodegenerat

Period of report

Feb 12, 2016

Accepted (ET)

Feb 17, 2016 · 5:57 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875045

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 12, 2016	F	628	$247.22	D	7,112	D
Common Stock	Feb 12, 2016	M	1,434	$0.00	A	8,546	D
Common Stock	Feb 12, 2016	F	556	$247.22	D	7,990	D
Common Stock	Feb 12, 2016	M	573	$0.00	A	8,563	D
Common Stock	Feb 12, 2016	F	270	$247.22	D	8,293	D
Common Stock	Feb 12, 2016	M	792	$0.00	A	9,085	D
Common Stock	Feb 12, 2016	F	373	$247.22	D	8,712	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F1	$0.00	Feb 12, 2016	M	1,434	D	—	Feb 12, 2019	Common Stock	1,434	11,906	D
Restricted Stock Unit^F2	$0.00	Feb 12, 2016	M	573	D	—	Feb 12, 2017	Common Stock	573	2,095	D
Restricted Stock Unit^F3	$0.00	Feb 12, 2016	M	792	D	—	Feb 12, 2017	Common Stock	792	797	D
Restricted Stock Unit^F2	$0.00	Feb 12, 2016	J	759	D	—	Feb 12, 2017	Common Stock	759	1,336	D
Restricted Stock Unit^F1	$0.00	Feb 12, 2016	J	1,900	D	—	Feb 12, 2019	Common Stock	1,900	10,006	D

Explanation of responses

F1The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F2The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F3The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
F4This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.